TABLE 1.
Baseline characteristics of the study population according to the enrolment period.
| Available (n) | Study population (n = 182) | < 2016 (n = 90) | > 2016 (n = 92) | P-value | |
| Age, y | 182 | 73 (63–80) | 70 (58–77) | 77 (69–82) | <0.001 |
| Male | 182 | 122 (67%) | 53 (58.9%) | 69 (75%) | 0.021 |
| AL amyloidosis | 182 | 86 (47.3%) | 58 (64.4%) | 28 (30.4%) | 0.001 |
| ATTR amyloidosis | 182 | 81 (44.5%) | 19 (21.1%) | 62 (67.4%) | 0.001 |
| Other etiologies | 182 | 15 (8.2%) | 13 (14.4%) | 2 (2.2%) | 0.001 |
| Biopsy-proven diagnosis | 182 | 124 (68.1%) | 87 (96.7%) | 37 (40.2%) | <0.001 |
| Scintigraphy-proven diagnosis | 182 | 58 (32%) | 3 (3.3%) | 55 (59.8%) | <0.001 |
| NYHA ≥ 3 | 177 | 79 (44.6%) | 46 (53.5%) | 33 (36.3%) | 0.021 |
| Systolic BP, mmHg | 169 | 120 (110–140) | 120 (110–140) | 120 (110–140) | 0.176 |
| Syncope | 182 | 19 (10.4%) | 12 (13.3%) | 7 (7.6%) | 0.20 |
| Hypertension | 182 | 99 (54.4%) | 40 (44.4%) | 59 (64.1%) | 0.008 |
| eGFR < 60 mL/min | 151 | 77 (51%) | 33 (50%) | 42 (45.6%) | 0.83 |
| eGFR, mL/min | 151 | 50 (36–75) | 59 (34–75) | 59 (40–76) | 0.484 |
| IHD | 182 | 12 (6.6%) | 5 (5.6%) | 7 (7.6%) | 0.58 |
| History of AF | 180 | 66 (36.7%) | 17 (19.1%) | 49 (53.8%) | <0.001 |
| Carpal tunnel | 181 | 44 (24.3%) | 6 (6.7%) | 38 (41.3%) | <0.001 |
|
| |||||
| Medications | |||||
|
| |||||
| BBs | 171 | 82 (48%) | 36 43.4%) | 46 (52.3%) | 0.244 |
| ACEi/ARBs | 171 | 86 (50.3%) | 36 (43.4%) | 50 (56.8%) | 0.079 |
| Diuretics | 171 | 143 (83.6%) | 69 (83.1%) | 74 (84.1%) | 0.866 |
| MRAs | 171 | 68 (39.8%) | 30 (36.1%) | 38 (43.2%) | 0.347 |
|
| |||||
| Electrocardiography | |||||
|
| |||||
| Rhythm at baseline | 182 | 0.145 | |||
| Sinus rhythm | 109 (59.9%) | 60 (66.7%) | 49 (53.3%) | ||
| AF | 61 (33.7%) | 24 (26.7%) | 37 (40.2%) | ||
| PM | 12 (6.6%) | 6 (6.7%) | 6 (6.5%) | ||
| HR, bpm | 145 | 75 (65–88) | 76 (68–90) | 70 (65–85) | 0.110 |
| RBBB | 182 | 30 (16.5%) | 10 (11.1%) | 20 (21.7%) | 0.053 |
| LBBB | 182 | 27 (14.8%) | 10 (11.1%) | 17 (18.5%) | 0.162 |
| LFAB | 182 | 31 (17%) | 12 (13.3%) | 19 (20.7%) | 0.189 |
| LVH | 182 | 21 (11.5%) | 9 (10%) | 12 (13%) | 0.521 |
| Q wave | 182 | 55 (30.2%) | 32 (35.6%) | 23 (25%) | 0.121 |
| Low QRS voltages | 182 | 64 (35.2%) | 37 (41.1%) | 27 (29.3%) | 0.097 |
|
| |||||
| Echocardiography | |||||
|
| |||||
| LVEDVi, mL/m2 | 155 | 42 (34–55) | 38 (30–51) | 45 (38–57) | 0.002 |
| IVS, mm | 174 | 16 (14–19) | 15 (14–18) | 17 (15–20) | 0.016 |
| PW, mm | 167 | 14 (12–16) | 14 (12–16) | 14 (12–17) | 0.347 |
| LVEF | 167 | 55% (47–63) | 57% (51–65) | 53% (41–62) | 0.021 |
| LVEF < 50% | 173 | 51 (29.5%) | 19 (22.1%) | 32 (36.8%) | 0.034 |
| E/E’ | 112 | 20 (14–27) | 20 (11–23) | 21.5 (16–28) | 0.035 |
| RFP | 124 | 61 (49.2%) | 32 (47.8%) | 29 (50.9%) | 0.729 |
| LA diameter, mm | 142 | 44 (39–50) | 43 (39–49) | 46 (40–51) | 0.101 |
| RA area, cm2 | 131 | 23 (18–26) | 22 (18–26) | 23 (19–27) | 0.466 |
| RV dysfunction | 165 | 91 (55.2%) | 46 (56.1%) | 45 (54.2%) | 0.808 |
| Biventricular dysfunction | 161 | 40 (24.8%) | 17 (21.3%) | 23 (28.4%) | 0.294 |
| Moderate-severe MR | 149 | 30 (20.1%) | 14 (20%) | 16 (20.3%) | 0.969 |
| Aortic stenosis | 159 | 21 (13.2%) | 5 (6%) | 16 (21.1%) | 0.005 |
| RV hypertrophy | 174 | 69 (39.7%) | 31 (36%) | 38 (43.3%) | 0.336 |
| Thickened IAS | 174 | 26 (14.9%) | 8 (9.3%) | 18 (20.5%) | 0.039 |
| Pericardial effusion | 174 | 69 (39.7%) | 37 (43%) | 32 (36.4%) | 0.369 |
ACEi, Angiotensin-converting enzyme inhibitor; AF, Atrial Fibrillation; AL, Amyloid light chain; ARBs, Angiotensin II Receptor Blockers; ATTR, Transthyretin Amyloidosis; BBs, Beta Blockers; BP, Blood Pressure; eGFR, estimated Glomerular Filtration Rate; HR, Heart Rate; IAS, Interatrial Septum; IHD, Ischemic Heart Disease; IVS, Interventricular septum; LA, Left Atrium; LBBB, Left Bundle Branch Block; LFAB, Left Fascicular Anterior Block; LVEDVi, Left Ventricular End Diastolic Volume index; LVEF, Left Ventricular Ejection Fraction; LVH, Left Ventricular Hypertrophy; MR, Mitral regurgitation; MRAs, Mineralocorticoid Receptors Antagonists; NYHA, New York Heart Association; PM, Pacemaker; PW, Posterior Wall; RA, Right Atrium; RBBB, Right Bundle Branch Block; RFP, Restrictive Filling Pattern; RV, Right Ventricle. Bold identifies parameters with p-value <0.05.